Haemonetics Holds Key Level. Gains to Follow?
The stock tested and held a key demand zone b/w $70-$82.
Since hitting $140 in August 2019, Haemonetics' stock is down 37% from its high print. It's trailed the S&P 500 over one year but outperformed over three and five-year periods.
What's its chart telling us?

- The stock held the $70.00-$82.30 demand (support zone).
- It last tested this zone in February & April, 2019 (purple arrow). And rallied ~70% over the next six months.
POTENTIAL CAGR | |
---|---|
Beginning Value | $82 |
Ending Value | $140 |
1-year CAGR | 70.5% |
3-year CAGR | 19.4% |
5-year CAGR | 11.2% |
7-year CAGR | 7.9% |
- Beginning Value = Support level at $82.
- Ending Value = Previous all-time at $140.
*These are potential returns based on the price making it back to its all-time high. There's no guarantee it will happen.
What they do:
Haemonetics ($HAE) makes hematology products that help improve patient care and reduce the cost of healthcare.
Note: Hematology is the study of blood and blood disorders. Learn more about hematology and why itโs essential.
They have three business units: Plasma, Blood Center, and Hospital.
- Plasma-This unit provides plasma collection devices, disposables, and software for biopharmaceutical companies.
- Blood Center-This unit makes blood collection and software products.
- Hospital-This unit makes devices for measuring the coagulation of blood. And disposables and software that facilitate blood transfusions and cell processing.
REVENUE BREAKDOWN | |
---|---|
Plasma | 46% |
Blood Center | 32% |
Hospital | 20% |
Other | 2% |
For more details on their business, start reading on page 2 of its annual report.
Their customers:
- Biopharmaceutical companies
- Blood collection groups and independent blood centers
- Hospitals and national health organizations
Distribution:
They have a direct sales force and independent distributors. They target the decision-makers within each organization.
Note: In fiscal 2020, 2019, and 2018, their ten largest customers accounted for 54%, 52%, and 45% of their net revenues.
KEY FACTS | |
---|---|
Ticker | $HAE |
Headquarters | Braintree, MA |
# of Employees | 3,300 |
Market Cap. | $4.53 billion |
TTM Revenue | $945.6 million |
Date Founded | 1971 |
IPO Year | 1991 |
Short Interest | 2.5% |
52-Week Range | $74-$131 |
KEY FINANCIALS | TTM, $ in millions |
---|---|
Revenue | $945.6 |
Gross Margin | 48.9% |
EBITDA | $240.7 |
EBITDA Margin | 25.5% |
Net Income | $95.5 |
Net Income Margin | 10.1% |
Free Cash Flow | $101.3 |
Free Cash Flow Margin | 10.7% |
RETURNS | TTM |
---|---|
Return on Assets | 7.0% |
Return on Invested Capital (ROIC) | 8.6% |
Return on Equity | 15.9% |
VALUATION MULTIPLES | |
---|---|
Forward Price/Revenues | 4.9x |
Trailing Price/Revenues | 4.8x |
Forward Price/Earnings | 31.4x |
Trailing Price/Earnings | 47.9x |